Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

ificant long-term revenue for the Company while building value for our shareholders," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris.

About the Phase 3 Program with Cetrorelix in BPH

Cetrorelix pamoate is currently in three Phase 3 trials involving more than 1,600 patients with symptomatic BPH in Canada, the United States and Europe.

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment was completed in October 2008, involves 420 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include ch
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... 30, 2014 OriginOil Inc. (OTC/QB: OOIL), ... process to clean up large quantities of water, announced ... Eckelberry reported on the launch of the company's CLEAN-FRACâ„¢ ... provided by partner STW Resources . , Immediately ... per day (bpd) and achieved a 99.8% reduction in ...
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Global Next-generation Sequencing Trends 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4
... with the 20th Anniversary of the Draper Prize, Draper Laboratory, in ... new website for students and adults to learn about the impact ... accomplishments of the 32 engineers who have been awarded "Engineering,s Nobel" ... ...
... 12 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... and six-month periods ended December 31, 2008. Revenues for ... compared to $3.7 million for the second quarter of ... for the three months ended December 31, 2008 compared ...
... Calif., Feb. 12 iZumi Bio, Inc., announced,today the ... and a,member of the company,s Board of Directors. ... Inc. which merged with Transcept Pharmaceuticals,Inc. in January 2009. ... , iZumi Bio is focused ...
Cached Biology Technology:New Educational Website Celebrates the Accomplishments of Engineers 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 4iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:9/30/2014)... Winners of The Economist,s prestigious Innovation awards 2014 will ... at the JW Marriott Hong Kong on Friday, October 10 th ... experiences and the lessons those hold for others. The awards, which ... past decade, will be presented at a ceremony in ... be the first time the ceremony has come to ...
(Date:9/29/2014)... a NASA story from 2009, "human activities in this area ... issue. Palm oil is increasingly grown for use as a ... processed foods. It has become the most widely produced edible ... years to surpass that of soybean oil. , The environmental ... be cleared to grow the crop, and the preferred method ...
(Date:9/29/2014)... Mountain pine beetles get a bad rap, and understandably ... trees over tens of millions of acres in the ... , But contrary to popular belief, these pests may ... those that have recently swept through the region. Instead, ... ecological severity of fires than these bark-boring beetles. , ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... developed a new technique for creating human embryonic stem ... cells. The fusion causes the adult cells to undergo ... developmental characteristics of human embryonic stem cells. , ... nuclear transfer (SCNT), a method that is currently used ...
... Remains of photosynthesizing microbes in prehistoric rocks suggest Earth ... techniques to previously unexamined rock formations has turned up ... decades-long scientific argument. , The study appears in the ... Olcott, a Ph.D. student of earth sciences in the ...
... with mice, researchers have found that nicotine triggers ... as heroin their addictively rewarding properties--including associating an ... nicotine does not directly activate the brain's opiate ... in the brain. , The researchers, led by ...
Cached Biology News:Researchers devise new technique for creating human stem cells 2Researchers devise new technique for creating human stem cells 3Researchers devise new technique for creating human stem cells 4Study casts doubt on 'Snowball Earth' theory 2Nicotine triggers the same brain reward circuitry as opiates 2
... EZ-Spread Plating Beads Sterile plating in ... glass rods and potentially hazardous ethanol flaming, ... choices of ready-to-use sterile packaging: dispenser bottle for ... plating, Fastest and easiest way to ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... a regulated environment, Pipette Tracker Pro ... that automates gravimetric pipette calibration and ... meets todays regulatory compliance requirements. Pipette ... that includes a full security implementation, ...
... the yolk protein Vtg in plasma from juvenile ... biomarker for endocrine disrupting chemicals (EDCs) with estrogenic ... an accepted screening test for the estrogenic effects ... EIA kit is a double-antibody immunometric (sandwich) EIA ...
Biology Products: